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Abstract
Background: The urokinase plasminogen activator receptor is highly expressed and its gene is amplified in about
50% of pancreatic ductal adenocarcinomas; this last feature is associated with worse prognosis. It is unknown
whether the level of its soluble form (suPAR) in urine may be a diagnostic-prognostic marker in these patients.
Methods: The urinary level of suPAR was measured in 146 patients, 94 pancreatic ductal adenocarcinoma and 52
chronic pancreatitis. Urine from 104 healthy subjects with similar age and gender distribution served as controls.
suPAR levels were normalized with creatinine levels (suPAR/creatinine, ng/mg) to remove urine dilution effect.
Results: Urinary suPAR/creatinine values of pancreatic ductal adenocarcinoma patients were significantly higher
(median 9.8; 25th-75th percentiles 5.3-20.7) than those of either healthy donors (median 0; 0-0.5) or chronic
pancreatitis patients (median 2.7; 0.9-4.7). The distribution of values among cancer patients was widespread and
asymmetric, 53% subjects having values beyond the 95th percentile of healthy donors. The values of suPAR/
creatinine did not correlate with tumour stage, Ca19-9 or CEA levels. Higher values correlated with poor prognosis
among non-resected patients at univariate analysis; multivariate Cox regression identified high urinary suPAR/
creatinine as an independent predictor of poor survival among all cancer patients (odds ratio 2.10, p = 0.0023),
together with tumour stage (stage III odds ratio 2.65, p = 0.0017; stage IV odds ratio 4.61, p < 0.0001) and female
gender (odds ratio 1.85, p = 0.01).
Conclusions: A high urinary suPAR/creatinine ratio represents a useful marker for the identification of a subset of
patients with poorer outcome.
Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the
leading causes of cancer-related death in the Western
world [1,2]. Up to 80% of patients have locally advanced
or metastatic disease at diagnosis; their median survival is
6 months and treatment, including chemotherapy and/or
radiotherapy, have very limited benefit in terms of
prolonging life [3,4]; the overall five year survival is less
than 5% [2]. Patients who undergo surgery have a better
prognosis and the addition of chemotherapy is more
effective in extending their lives [5,6]. Earlier diagnosis
can therefore have strong beneficial effect on survival.
Extensive research has focused on finding reliable diag-
nostic/prognostic molecular markers. Unfortunately,
many of the candidate markers have been of no clinical
use because of poor specificity and/or sensitivity [7], and
the only FDA approved serum marker for pancreatic can-
cer to date remains CA19-9. New potential markers are
being constantly tested and some have appeared to be
superior to CA19-9, especially when used in combination
[8-10]. The majority of these studies used plasma or
serum. Urine, however, being a plasma ultrafiltrate, may
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contain cancer-derived molecules at a higher concentra-
tion than into the blood; it may also contain molecules
that are quickly removed from the bloodstream and thus
undetectable in plasma samples.
We focused on the uPA/uPAR system (urokinase-type
plasminogen activator and its receptor). uPA is a serine
protease that specifically activates plasminogen to plasmin.
It is synthesized as an inactive precursor (pro-uPA) that
undergoes proteolytic activation. Pro-uPA and uPA bind
with high affinity to a specific receptor, uPAR (CD87),
which is extracellularly docked to the plasma membrane
by a glycosylphosphatidylinositol (GPI) anchor [11-13].
uPAR is constituted by three repeats (D1, D2 and D3), of
about 90 residues each, connected by two linker regions
and defining specific protein domains [14,15]. The linker
region between domains D1 and D2 is highly susceptible
to endoproteolytic cleavage by proteinases such as uPA
itself, plasmin, elastase, matrix metalloproteinases and
cathepsin G [16-19].
The binding of uPA to uPAR induces cell migration,
adhesion and proliferation [13,20,21]. The soluble form
of uPAR (suPAR), generated by proteases or cleavage of
the GPI anchor by phospholipases, is essential for these
processes: it behaves as a chemokine by binding either
integrins or, in its cleaved form, a seven-transmembrane
receptor (FPRL-1), attracting monocytes to the site of
inflammation [13,22,23].
The uPA/uPAR system is also involved in cancer patho-
genesis and soluble uPAR was first found in the blood and
ascitic fluids of ovarian cancer patients; subsequently
uPAR and its soluble form were respectively reported in
tissues and in serum/plasma of patients with other cancer
types [24-26]. Enhanced serum suPAR concentrations
were indicative of poor prognosis in a group of ovarian
carcinoma patients [27] and members of the plasminogen
activator system including uPA, PAI-1 and uPAR itself,
have been suggested to have prognostic value in a large
number of human cancers [26,28]. SuPAR has been
detected in urine of healthy women and patients with
diverse ovarian-related diseases; in the same work the cor-
relation between the plasma and urinary levels of suPAR
was demonstrated. However, due to the limited number of
samples analyzed, the diagnostic and prognostic value of
these data was not assessable [29]. The same authors
showed that primary tumour extracts contain both intact
and cleaved suPAR but this last form is missing in serum
samples from the same patients; it can however be
detected, together with the intact molecule, in ascites and
urine [30]. Urinary suPAR levels were also elevated in a
group of patients affected by bladder carcinoma but differ-
ences were not distinct enough to reach significance as a
diagnostic-prognostic marker [31].
The majority of pancreatic adenocarcinomas express
urokinase-type plasminogen activator (uPA) and its
receptor (uPAR) [32,33], but only about a half of them
show a marked increase. This feature has been recently
associated with uPAR gene amplification and defines a
clinical group with poorer prognosis [34]. However, these
studies only rely on pancreatic tissue specimens and the
presence of suPAR has not been evaluated in urine of
these patients. The purpose of this study was to investi-
gate the presence of suPAR in urine of PDAC patients to
define its diagnostic and prognostic significance.
Methods
Patients and healthy donors
According to published data, uPAR is markedly overex-
pressed only in a fraction of pancreatic cancer patients.
We thus hypothesized that only a subgroup of patients
would display increased urinary suPAR levels as well. To
estimate the sample size we ran a preliminary power ana-
lysis; we hypothesized a difference in proportions of sub-
jects with increased suPAR levels between patients and
controls of 30%. A sample size of 100 patients and 100
controls was adequate by chi-square analysis with a
power of 0.95.
We used plasma and urine from 94 PDAC patients (50
females, 44 males; mean age 60 yrs, SD 10), 52 chronic
pancreatitis (15 females, 37 males; mean age 50 yrs, SD
12), and 104 healthy controls (48 females, 56 males;
mean age 53 yrs, SD 19) enrolled from January 2004 to
December 2006; all evaluable chronic pancreatitis cases
were included. Written, informed consent was obtained
according to a protocol approved by local ethics commit-
tee. Follow-up of patients ended in December 2009;
PDAC patients evaluable for survival were 91. Median
follow-up was 10.5 months (range 0.5-56.6) with 82
deaths of disease and 9 censored subjects exiting follow-
up at different time points (1 dead of other causes, 2 alive
with disease, 6 dropped out).
TNM stage (UICC/AJCC 2010) was available for 91
patients: stage I (T1,2 N0 M0: tumour limited to pancreas
[T1,2], no regional lymph node metastasis [N0], no distant
metastasis [M0]) n = 2, stage II (T3 N0 M0 or T1,2,3 N1
M0: tumour extends beyond pancreas [T3] and/or has
lymph node metastases [N1] without involving the celiac
axis or superior mesenteric artery) n = 21, stage III (T4
anyN M0: tumour involves the celiac axis or superior
mesenteric artery [T4] but without distant metastasis) n =
34, stage IV (anyT anyN M1: tumour with distant metasta-
sis [M1]) n = 34. Fifty patients (53%) underwent surgery,
21 of them were submitted to radical resections, 22 to pal-
liative and 7 to explorative procedures. No patient had
renal impairment according to serum creatinine measure-
ments. Staging of inoperable patients was based on com-
puted tomography, ultrasound imaging data and fine
needle aspiration cytology. None of the enrolled patients
had received chemotherapy before blood and urine
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collection. Ca 19-9 and CEA data were available in 79 of
the 94 PDAC patients and their respective median values
were 286.5 U/ml (range 1-58791) and 3.3 ng/ml (range
0.3-471.8). Performance status according to Karnofsky
classification was available for 82 of 94 PDAC patients; its
value was 100% for 14 patients, 80-90% for 58 patients and
under 70% for 10 patients. The presence of cancer in
chronic pancreatitis patients was excluded using imaging
techniques (ultrasonography, CT scan, MR), endoscopy
and fine needle aspiration cytology or biopsy. All patients
were submitted to follow-up for a minimum of two years,
according to a well-established procedure at our national
referral centre for pancreatic disease[35,36].
Collection and handling of samples
Blood and/or urine were collected from fasting patients
upon hospitalization. Plasma was recovered after centri-
fugation of EDTA-treated blood for 5 min at 200 × g and
further centrifuged for 30 min at 3000 × g to remove pla-
telets and cellular debris. Urine was centrifuged for 30
min at 3000 × g. Samples were aliquoted in 1.5 ml tubes,
snap-frozen in liquid nitrogen and stored at -80°C until
they were analyzed. When used, aliquots were slowly
thawed in ice, thoroughly mixed and centrifuged for 5
min at 16000 × g to remove precipitate if present. Mea-
surements were done by personnel blinded to the patient
diagnosis. Creatinine was measured with the CREA crea-
tinine Jaffé method kit (Roche Diagnostics, Mannheim,
Germany) and read on a Roche/Hitachi MODULAR
ANALYTICS P800 according to the manufacturer guide-
lines. CA19-9 and CEA levels were determined upon
patients hospitalization with the LIAISON® CA19-9™
and CEA kits; both kits were used on a LIAISON® reader
(DiaSorin, Saluggia, VC Italy) according to the manufac-
turer instructions; these were standard diagnostic proce-
dures of the Hospitals of Verona at the time of
measurement.
Capture ELISA assay for the detection of soluble uPAR
Soluble uPAR was detected in plasma and urine samples
using the AssayMax Human Urokinase Receptor (uPAR)
ELISA Kit (Assaypro, St. Charles, MO, USA), according to
the manufacturer’s guidelines. All Samples (plasma and
urine) were diluted 1:5 in the supplied buffer and mea-
sured in duplicate. Absorbance was measured at 450 nm
on a Synergy plate reader (Biotek, Winooski, VT, USA)
and concentrations determined with the Gen5® program
(Biotek, Winooski, VT, USA).
The ability of the above kit to detect all isoforms of
suPAR was confirmed by analyzing ten urine samples,
with suPAR concentrations spanning the full range of
detectable values, also with the method described by
Resnati et al [37].
Briefly, black immunoassay plates (Maxisorp Nunc,
Langenselbold, Germany) were coated for 16 h at 4°C
with 100 µl/well of anti-uPAR monoclonal antibody R4
diluted 1 µg/ml, in 0.1M carbonate buffer, pH 9.5. After
rinsing three times with 300 µl PBS containing 0.1%
Tween® 20, the wells were treated for 30 min at 37°C
with 100 µl 2% BSA in PBS and again washed three
times with 300 µl PBS containing 0.1% Tween® 20. The
wells were then incubated for 2 h at 37°C with 100 µl of
either purified suPAR protein at different concentrations
or 1:5 diluted samples in PBS, 1% BSA. After three
washes with PBS/0.1% Tween® 20, the wells were incu-
bated for 1 h at 37°C with 100 µl anti-uPAR polyclonal
antibody SI369, 1 µg/ml in PBS/1% BSA. After three
washes with PBS/0.1% Tween® 20, the wells were incu-
bated for 1 h at 37°C with 100 µl goat anti-rabbit immu-
noglobulins/HRP conjugate (GE Healthcare, Milan,
Italy). After three washes with PBS/0.1% Tween® 20,
100 µl of freshly made Amplex Red (Invitrogen, Milan,
Italy) substrate solution (5 µM Amplex Red in 50 mM
sodium phosphate, pH 7.4 with the addition of 10 µl
H2O2 10 vol.) were added. After 1 hour incubation at
room temperature in the dark, HRP activity was
detected by measuring fluorescence with a microplate
reader (Victor3, Perkin Elmer) set for excitation in the
range of 530-560 nm and emission-detection at 590 nm.
Each sample was corrected for background fluorescence.
The antibody R4 was a kind gift by Dr. Gumilla Hoyer-
Hansen [38]; the antibody SI369 was produced in our
laboratory as previously described [37].
Comparison of the two methods by Pearson linear
correlation yielded R2 = 0.95 (p < 0.0001); mean differ-
ence between measurement was -0.3 ng/ml with a stan-
dard error of 1.2.
Statistical and survival analysis
Global analysis of suPAR/creatinine values was per-
formed using Kruskal-Wallis test followed by Mann-
Whitney test for multiple comparisons among the
patients groups. Statistical tests were corrected for the
large number of ties in the healthy donors group. Propor-
tions where analyzed by Fisher’s exact test. Correlation
between suPAR/creatinine and other parameters was
analyzed using Spearman’s rank correlation for ordinal or
continuous variables.
For comparison of Kaplan-Meier survival curves we
used Mantel-Cox log-rank test; for multivariate survival
analysis we used stepwise Cox proportional hazards
regression; selection of the best model was performed
using the “backward elimination” algorithm. For all the
analyses a p-value below 0.05 was considered as signifi-
cant. Graphs and univariate analyses were performed
using Graphpad Prism® version 5.00 for Mac (GraphPad
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Software, San Diego California USA, http://www.graph-
pad.com) and Gnumeric software (http://projects.gnome.
org/gnumeric), multivariate Cox regression was done
with R (version 2.10) using survival library (version
2.35.8) [39,40].
Results
Plasmatic and urinary suPAR levels are correlated
The correlation of plasmatic and urinary suPAR values
(Figure 1) was assessed using the first 36 PDAC patients.
A significant though limited correlation between the two
parameters was found (Spearman r = 0.54; p < 0.001; n =
36), thus showing that urinary suPAR levels vary in accor-
dance with plasmatic levels only to a limited extent. More-
over, 13 of 21 patients showed elevated urinary suPAR
without a corresponding increase in plasmatic levels.
Given this difference and since urines are the only of the
two sample types where both intact and cleaved suPAR
accumulate according to published data [30], we measured
only urinary suPAR for the remaining patients. The plas-
matic levels of suPAR are herein reported in ng/ml, while
the levels of urinary suPAR levels are reported as suPAR/
creatinine ratio and thus expressed as ng/mg. We used
creatinine normalization, a standard clinical practice for
many urinary markers, to correct the effect of differences
in dilution of the urine (due to water reabsorption) and to
improve the consistency of the assay, since urinary excre-
tion of any biomarker is affected by the glomerular filtra-
tion rate and the resultant urinary flow. This method has
been described for urinary suPAR by Sier et al [29].
Urinary suPAR levels in PDAC patients are higher than in
CP patients and healthy controls
We measured the levels of suPAR/creatinine in the
urine of 146 patients affected by pancreatic diseases and
104 healthy donors. The 146 patients included 94
affected from pancreatic ductal adenocarcinoma and 52
from chronic pancreatitis. Clinical data of PDAC
patients are summarized in Table 1.
A scatter plot of the values of suPAR/creatinine in the
two groups of patients and in healthy donors is shown in
Figure 2, while a summary of suPAR data for patients
and controls is presented in Table 2. Healthy controls
bore low or undetectable levels of suPAR/creatinine
(median 0; 25th-75th percentiles 0-0.5), with 95% of the
subjects below 9.1 ng/mg. The values of PDAC (median
9.8; 5.3-20.7) and CP (median 2.7; 0.9-4.7) groups were
compared to each other and to those of healthy controls
by Kruskal-Wallis test followed by Mann-Whitney post-
hoc test and resulted to be significantly (p < 0.0001) dif-
ferent. The distributions of values measured in PDAC
patients, CP patients and healthy controls were asym-
metric, with skewness of 5.48, 3.40 and 3.25 respectively;
a fraction of PDAC patients displayed high suPAR/creati-
nine levels while the rest had values close to CP patients
and healthy donors. To better distinguish PDAC patients
with increased suPAR/creatinine levels, considering the
ROC curve analysis, we took the 95th percentile of
healthy donors as a threshold and calculated the propor-
tion of subjects with either high (> 9.1 ng/mg) or low (≤
9.1 ng/mg) suPAR/creatinine ratio in each group. This
threshold was used for all the subsequent analyses as a
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Figure 1 Correlation between plasma suPAR concentration and
urinary suPAR/creatinine level in pancreatic adenocarcinoma
patients.
Table 1 Clinical data of pancreatic adenocarcinoma
patients
Characteristics Value
Number of patients 94
Males/Females 44/50
Mean Age (SD), years 60 (10)
Subjects with follow-up data available 91
Censored subjects (Drop-outs) 9 (6)
Surgery n
Resected 21
Not resected
Palliative surgery 22
Explorative surgery 7
Not operated 41
Stage n
I (T1,2 N0 M0) 2
II (T3 N0 M0 or T1,2,3 N1 M0) 21
III (T4 anyN M0) 34
IVB (anyT anyN M1) 34
Follow-up from diagnosis, median (25th-75th
percentiles)
Months
Overall 10.5 (5.3-18.5)
Resected (n = 21) 22.7 (13.7-
31.8)
Not resected (n = 70) 7.9 (5.0-15.5)
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mean to distinguish patients with abnormally increased
suPAR/creatinine. As Table 2 shows, 53.2% of PDAC
patients had values of suPAR/creatinine higher than the
threshold while only 9.6% of CP patients had values
beyond the threshold; the proportions of subjects with
high values of suPAR/creatinine were compared to
healthy donors by Fisher’s exact test and only PDAC
patients showed a significant difference (p < 0.0001).
Finally, comparing proportions of subjects with high
urinary suPAR/creatinine levels in healthy individuals
and CP patients vs. PDAC patients, the specificity of the
test was 93.6% (95% CI 88.6-96.5), with a sensitivity of
53.2 (95% CI 43.2-62.9).
Urinary suPAR/creatinine ratio shows no correlation with
tumour stage, CA19-9 and CEA
We verified the correlation between urinary suPAR/
creatinine levels and other commonly used diagnostic
parameters for PDAC patients. Spearman analysis
showed no correlation between values of suPAR/creati-
nine and either CA19-9 (r = 0.195; p = 0.082) or CEA (r
= 0.103; p = 0.337). Similarly, there was no significant
association between suPAR/creatinine values and age
(Spearman r = -0.117; p = 0.489). As for categorical
variables, we performed the analysis by splitting patients
with high (> 9.1 ng/mg) or low (≤ 9.1 ng/mg) suPAR/
creatinine ratio, according to the above chosen thresh-
old. The proportions of patients with elevated suPAR/
creatinine were not significantly different in the sub-
groups of resectable (stage I/II), locally advanced (stage
III) and metastatic (stage IV) subjects. Indeed, patients
with high urinary suPAR/creatinine were 14 of 23 (61%)
among stageI/II, 20 of 34 (59%) among stage III and 13
of 34 (38%) among stage IV; the group of stage IV
patients displayed a smaller proportion of subjects with
high suPAR/creatinine levels, although this difference
was not statistically significant (Fisher’s exact test; p =
0.17). As for gender, 25 of 43 male (58%) patients and
22 of 48 (46%) female patients showed high suPAR/crea-
tinine levels (Fisher’s exact test; p = 0.29). Similarly, no
association was found between high suPAR/creatinine
and performance status of patients: six of ten (60%)
patients with a performance status under 70% had ele-
vated urinary suPAR/creatinine compared to 28 of 58
(48%) patients with a performance status of 80-90% and
10 of 14 (71%) patients with a performance status of
100% (Fisher’s exact test; p = 0.28).
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Figure 2 Urinary suPAR/creatinine levels in patients and
controls. Scatter plot showing urinary suPAR/creatinine levels in:
Healthy = healthy donors, CP = chronic pancreatitis, PDAC =
pancreatic ductal adenocarcinoma. Bars indicate median values.
Post-hoc comparisons (Mann-Whitney test) between clinical groups
are indicated in the upper bars.
Table 2 Summary of suPAR/creatinine data for patients and controls
Healthy Controls Chronic Pancreatitis Ductal Carcinoma
Number of cases 104 52 94
Mean Age (SD) 53 (19) 50 (12) 60 (10)
Males/females 56/48 37/15 44/50
suPAR/creatinine median
(25th-75th percentile)
0 (0-0.5) 2.7 (0.9-4.7) 9.8 (5.3-20.7)
Comparison with controls median* - p < 0.0001 p < 0.0001
Elevated suPAR/creatinine° 4.8% 9.6% (p = 0.32) 53.2% (p < 0.0001)
°Value beyond 9.1 ng/mg (healthy donors’ 95th percentile) was used as a threshold, comparison with proportions of healthy controls by fisher’s exact test.
* Mann-Whitney test
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Increased urinary suPAR/creatinine ratio is an
independent adverse prognostic factor among non-
resected pancreatic cancer patients
To assess the prognostic significance of high urinary
suPAR/creatinine, PDAC patients’ data were analyzed by
multivariate stepwise Cox regression. Variables tested as
independent predictors of survival were a high (> 9.1
ng/mg) urinary suPAR/creatinine level, tumour stage,
gender and age. Tumour stage was strongly linked to
resection, since all 23 stage I or II patients but two had
been resected while all 68 stage III or IV patients had
not; therefore differences between stages I-II and III-IV
also included resection’s effects. The results are sum-
marized in Table 3: an elevated urinary suPAR/creati-
nine level resulted to be associated with poorer survival
with an odds ratio of 2.10 (p = 0.0023). Other variables
that significantly affected overall survival were female
gender (odds ratio 1.85) and tumour stage, the latter
showing the most relevant prognostic impact (stage III
odds ratio 2.65; stage IV odds ratio 4.61). Both stages III
and IV showed worse survival compared to lower stages
(i.e. patients that had been resected); however, confi-
dence intervals of odds ratios for stages III and IV over-
lapped, indicating that differences in survival between
these two groups of patients didn’t reach statistical
significance.
At univariate Kaplan-Meier survival analysis, patients
with a high urinary suPAR/creatinine level showed a trend
to poorer survival (median survival of 8 months vs. 14
months of patients with low suPAR/creatinine). However,
the two survival curves overlapped after 18 months yielding
a not significant (p = 0.20) log-rank test. Considering the
strong impact of resection on overall survival and tumour
progression, the analysis was also performed after stratify-
ing patients by resection as shown in Figure 3. The small
subgroup of resected patients (n = 21) had no significant
difference in survival according to suPAR urinary levels,
while non-resected patients survival curves showed a sig-
nificant separation (p = 0.034). After further stratification
of unresectable patients into metastatic (n = 34) vs. not
metastatic (n = 36), patients with high suPAR/creatinine
levels still showed a trend to poorer survival in both sub-
groups. Indeed, metastatic patients with high suPAR/creati-
nine had a median survival of 7 months vs. 14 months of
the ones with low suPAR/creatinine; not metastatic
patients with high suPAR/creatinine had a median survival
of 7 months vs. 12 months of those with low suPAR/creati-
nine. However, the survival differences only approached
statistical significance (log-rank test: p = 0.08 for metastatic
patients; p = 0.1 for not metastatic patients). Taken
together, curves of resected and non-resected patients with
either low or high suPAR/creatinine (Figure 3D) were sig-
nificantly separated (p < 0.0001), showing a trend to pro-
gressively worse prognosis (p = 0.014). Median survivals
were respectively 24 months from diagnosis for resected
patients, 13 months for non-resected with normal suPAR/
creatinine, 7 months for non-resected with high suPAR/
creatinine.
Discussion
We report in the present study that high levels of
suPAR in the urine of patients suffering from pancreatic
ductal adenocarcinoma identify a clinically high risk
subgroup.
Indeed, 53% of our 94 patients had urinary suPAR/crea-
tinine values above the 95th percentile of healthy donors at
9.1 ng/mg, while the remaining 47% had suPAR/creatinine
levels below that value. This threshold for urinary suPAR/
creatinine was capable of identifying a group of patients
with worse prognosis. Unresected patients displaying high
urinary values of suPAR/creatinine showed a significantly
increased mortality at univariate survival analysis, with
surviving patients dropping to 22% after 9 months; at the
same time point, 60% of the patients with low suPAR urin-
ary levels were still alive. The association between high
urinary suPAR/creatinine levels and poorer survival was
not evident among resected patients at univariate analysis,
possibly due to the small sample size (n = 21) of this
patients group. However, the link between high urinary
suPAR levels and worse prognosis was confirmed by mul-
tivariate survival analysis: Cox regression including both
resected and unresected patients identified a high suPAR/
creatinine level as an independent predictor of poor prog-
nosis (odds ratio = 2.10).
The indication by multivariate survival analysis that
urinary suPAR/creatinine gives additional prognostic
information independent of that given by tumour stage is
further supported by proportions analysis that showed the
absence of correlation between tumour stage and suPAR/
creatinine. In fact, patients with resectable (stage I and II),
locally advanced (stage III) or metastatic (stage IV)
tumours showed a similar proportion of cases displaying
high suPAR/creatinine urinary levels (p = 0.17).
Table 3 Results of Cox regression analysis of pancreatic
ductal adenocarcinoma patients (n = 91)
Variable Odds
Ratio
95% CI p
Gender = female 1.85 1.16 -
2.96
0.01
Stage = I, II 1 - -
Stage = III 2.65 1.45 -
4.87
0.0017
Stage = IV 4.61 2.42 -
8.76
<
0.0001
High (> 9.1 ng/mg) suPAR/
creatinine
2.10 1.31 -
3.36
0.0023
Age 1.02 1.00-1.04 0.067
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Our work showed that half of PDAC patients had
markedly elevated suPAR/creatinine values and poorer
prognosis, while the other half of PDAC patients had
values comparable to those of chronic pancreatitis
patients and healthy subjects. Interestingly, previous
immunohistochemical studies reported that the level of
uPAR in primary pancreatic adenocarcinoma was higher
than in normal pancreas and tended to be associated
with a worse prognosis [32-34]. In particular, Hilden-
brand et al showed that virtually all (48 of 50) primary
carcinomas overexpress uPAR compared to normal pan-
creatic tissue by immunohistochemistry, and that 52% of
them had uPAR gene amplification by FISH analysis.
This latter feature correlated with worse prognosis and
with a higher protein concentration in the tumour as
quantitatively measured by ELISA on tissue lysates;
conversely, tumours without gene amplification and
chronic pancreatitis samples had comparably lower con-
centrations of uPAR [34].
Compared to its measurement on the tumour tissue,
the measurement of suPAR in urine provides at least
three advantages. First, the measurement does not
require tumour biopsies, and can thus be performed on
both resectable subjects, before and after surgery, and on
unresected patients. Second, the measurements can be
taken repeatedly and may be used in the follow-up of
patients. Third, the samples are obtained by absolutely
non-invasive methods, reducing the need for patient hos-
pitalization. One drawback of urinary markers is their
dependence on glomerular filtration rate: in the case of
renal impairment or failure, the ratio between creatinine
and protein markers levels become unreliable.
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Figure 3 Univariate survival analysis of pancreatic adenocarcinoma patients. Kaplan-meier analysis of pancreatic adenocarcinoma patients
based on surgery and suPAR/creatinine levels; curves compared by Mantel-Cox log-rank test, brackets illustrate 95% CI of survival. A) survival
difference between resected patients bearing levels of suPAR/creatinine higher or lower than 9.1 ng/mg (95th percentile of healthy donors) is
not significant (p = 0.46). B) Difference in survival between non resected patients according to suPAR/creatinine levels (p = 0.034). C) Survival
difference between resected and non-resected patients without considering suPAR/creatinine levels (p = 0.0001). D) Survival of resected vs. non-
resected patients with either low or high suPAR/creatinine (log-rank test p < 0.0001, log-rank test for trend between curves p = 0.014).
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Our data also show that suPAR/creatinine values are
independent from other commonly used diagnostic and
prognostic parameters (CA19-9, CEA), and thus can be
used in synergy with them, providing an additional layer
of information. As for its diagnostic performance, a high
(>9.1 ng/mg) urinary suPAR/creatinine ratio showed
53.2% sensitivity and 93.6% specificity in diagnosing
pancreatic adenocarcinoma. Given its high positive pre-
dictive value and considering a doubtful clinical situa-
tion in which other parameters do not yield a clear
answer, a high urinary suPAR/creatinine level may be
useful in the decision making process.
Conclusions
Our data show that suPAR urinary levels are increased in
a large subgroup of patients suffering from pancreatic duc-
tal adenocarcinoma and such an increase is rarely seen
among patients with chronic pancreatitis. This increase is
associated to poorer survival and the prognostic informa-
tion given by urinary suPAR levels is independent of that
furnished by tumour staging. Thus, a high urinary suPAR/
creatinine ratio represents a useful marker for the identifi-
cation of a subset of patients with clinical high risk of
poorer outcome.
Abbreviations
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